GoodRx Holdings (GDRX) Payables (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Payables data on file, last reported at $14.5 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 4.8% year-over-year to $14.5 million; the trailing twelve-month figure through Mar 2026 stood at $14.5 million (down 4.8% YoY), and the FY2025 full-year result was $19.4 million, up 37.26% from the prior year.
• Payables slipped to $14.5 million in Q1 2026, from $19.4 million in the prior quarter.
• In the past five years, Payables ranged from a high of $36.3 million in Q4 2023 to a low of $6.8 million in Q2 2023.
• A 5-year average of $19.2 million and a median of $16.8 million in 2022 frame the typical range for Payables.
• Across the five-year window, Payables surged 203.13% in 2023 and plunged 62.34% in 2024, its largest moves.
• Tracing GDRX's Payables over 5 years: stood at $17.7 million in 2022, then soared by 104.89% to $36.3 million in 2023, then tumbled by 61.02% to $14.1 million in 2024, then jumped by 37.26% to $19.4 million in 2025, then dropped by 25.15% to $14.5 million in 2026.
• Business Quant data shows GDRX's Payables at $14.5 million in Q1 2026, $19.4 million in Q4 2025, and $28.7 million in Q3 2025.